glp 1 gip glucagon triple agonist Strategic Design of GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects Design, synthesis, and structure-activity relationship

Depending on the condition being investigated, symptoms may include fatigue, night sweats, unexplained weight loss, jaundice, or abnormal bruising

Diabetes Obes Metab 19(4):524536 Husain M, Bain SC, Holst AG, Mark T, Rasmussen S, Lingvay I (2020) Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

El-Benhawy SA, Abdelrhman IG, Sadek NA, Fahmy EI, AboGabal AA, Elmasry H, et al

Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2

doi: 10.1159/000126883 92 JaffeCAHoPJDemott-FribergRBowersCYBarkanAL